Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Neurogene Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
NGNE
Nasdaq
8731
https://www.neurogene.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Neurogene Inc
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
- Apr 22nd, 2024 8:36 pm
Neurogene Inc (NGNE) Reports Financial Results for Q4 and Full Year 2023
- Mar 20th, 2024 9:31 am
With 32% ownership, Neurogene Inc. (NASDAQ:NGNE) has piqued the interest of institutional investors
- Mar 19th, 2024 10:48 am
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
- Mar 18th, 2024 8:14 pm
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial
- Mar 4th, 2024 12:30 pm
Neurogene to Participate in Upcoming Investor Conferences
- Feb 29th, 2024 12:30 pm
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer
- Jan 16th, 2024 12:00 pm
Neurogene Announces Business Update and 2024 Outlook
- Jan 5th, 2024 12:00 pm
Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million
- Dec 19th, 2023 12:00 pm
Scroll